Back to Search

Phase II Study of a Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer


  • Protocol Number: 202104143
  • Principal Investigator: Ward, Jeffrey
  • Cancer Types: Lung

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

Protocol Interventions